The firms are combining forces to get their cancer screening and diagnostic platforms into more hospitals in the US.

In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.

The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.

After a promising feasibility study showing the potential of its natural language processing models, MSK has ambitions to use them in patient care.

Researchers will use the funds to identify molecular signatures linked to different disease subtypes and test drugs on brain organoids.